Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to manufacture monoclonal antibody-based therapeutics. We also supply several growth factor products used to increase cell culture productivity in biomanufacturing. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the biologics purification process. Repligen’s corporate headquarters are located in Waltham, MA, USA; we have an additional manufacturing facility in Lund, Sweden.
Company Growth (employees)
Type
Public
HQ
Waltham, US
Founded
1981
Size (employees)
236 (est)+41%
Repligen was founded in 1981 and is headquartered in Waltham, US

Repligen Office Locations

Repligen has offices in Waltham, Lund
Waltham, US (HQ)
100 41 Seyon St
Lund, SE
47 Sankt Lars väg

Repligen Metrics

Repligen Financial Metrics

Revenue (2016)

$104.5 m

Revenue growth (2015-16), %

25%

Net income (2016)

$11.7 m

Market capitalization (21-Mar-2017)

$1.2 b

Closing share price (21-Mar-2017)

$35

Cash (31-Dec-2016)

$122.2 m
Repligen's current market capitalization is $1.2 b.
Repligen's revenue was reported to be $104.5 m in FY, 2016 which is a 25.1% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$68.2 m$63.5 m$83.5 m$104.5 m

Revenue growth, %

(7%)31%25%

Gross profit

$45.7 m$35.5 m$48.3 m

Gross profit Margin, %

67%56%58%

Operating expense total

$22.8 m$24.8 m$34.5 m$88.6 m

EBIT

$22.9 m$10.7 m$13.8 m$16 m

EBIT margin, %

34%17%16%15%

Interest expense

$27.8 k$50 k$32 k$3.8 m

Pre tax profit

($1.6 m)$11.1 m$13.4 m$11.7 m

Income tax expense

$15.7 k$3 m$4.1 m$11 k

Net Income

$16.1 m$8.2 m$9.3 m$11.7 m
FY, 2013FY, 2014FY, 2015FY, 2016

Cash

$39.8 m$35.4 m$54.1 m$122.2 m

Accounts Receivable

Inventories

$1.2 m$2.1 m$2.1 m$1.6 m

Current Assets

$86.4 m$80.9 m$103.3 m$184.2 m

PP&E

$12.5 m$14.5 m$13.8 m$15 m

Goodwill

$994 k$14.2 m$14.3 m$59.5 m

Total Assets

$118.6 m$128.3 m$146.2 m$288.9 m

Accounts Payable

$1.7 m$3.9 m$6.7 m$5.1 m

Current Liabilities

$11.3 m$10.7 m$18.8 m$21.1 m

Additional Paid-in Capital

$190.6 m$198.1 m$202.5 m$242 m

Retained Earnings

($89.1 m)($80.9 m)($71.5 m)($59.9 m)

Total Equity

$103.9 m$111.7 m$122.7 m$168.8 m

Financial Leverage

1.1 x1.1 x1.2 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($1.6 m)$8.2 m$9.3 m$11.7 m

Depreciation and Amortization

$1.3 m$4 m$4.6 m$5.3 m

Accounts Receivable

$3.6 m($1.6 m)($3.7 m)($3.2 m)

Inventories

($870.3 k)($860.1 k)($6.1 m)($6.2 m)

Accounts Payable

$247.2 k$2.3 m$3 m($1.8 m)

Cash From Operating Activities

$2.3 m$18.4 m$15.1 m$7.5 m

Purchases of PP&E

($575.5 k)($5.6 m)($2.6 m)($4.3 m)

Cash From Investing Activities

($5 m)($19.8 m)$4.8 m($49.2 m)

Income Taxes Paid

$2.5 m$4.9 m$4 m

Repligen Market Value History

Repligen Online Presence

Repligen Company Life

You may also be interested in